KR101151117B1 - 경구 투여가능한 고체 제약 조성물의 제조 방법 - Google Patents
경구 투여가능한 고체 제약 조성물의 제조 방법 Download PDFInfo
- Publication number
- KR101151117B1 KR101151117B1 KR1020067010283A KR20067010283A KR101151117B1 KR 101151117 B1 KR101151117 B1 KR 101151117B1 KR 1020067010283 A KR1020067010283 A KR 1020067010283A KR 20067010283 A KR20067010283 A KR 20067010283A KR 101151117 B1 KR101151117 B1 KR 101151117B1
- Authority
- KR
- South Korea
- Prior art keywords
- pharmaceutical composition
- active compound
- tablet
- oxo
- granulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Abstract
Description
시험관내 방출 | ||||
15분 | 30분 | 45분 | 60분 | |
정제 A | 87% | 92% | 93% | 94% |
정제 B | 94% | 95% | 96% | 96% |
Claims (21)
- (a) 5-클로로-N-({(5S)-2-옥소-3-[4-(3-옥소-4-모르폴리닐)-페닐]-1,3-옥사졸리딘-5-일}-메틸)-2-티오펜카르복스아미드 (I) [활성 화합물 (I)]을 친수화 형태로 포함하는 제1 과립을 습윤 과립화로 제조하는 단계, 및(b) 이어서, 적절하다면 제약상 적합한 첨가제를 첨가하여 상기 과립을 제약 조성물로 전환시키는 단계를 특징으로 하는, 활성 화합물 (I)을 친수화 형태로 포함하는 경구 투여가능한 고체 제약 조성물의 제조 방법.
- 제1항에 있어서, 이용되는 습윤 과립화 방법이 유동층 과립화임을 특징으로 하는 방법.
- 제1항 또는 제2항에 있어서, 활성 화합물 (I)이 결정질 형태로 사용되는 것을 특징으로 하는 방법.
- 제3항에 있어서, 활성 화합물 (I)이 미분 형태로 사용되는 것을 특징으로 하는 방법.
- 제1항 또는 제2항에 있어서, 과립화액 중에 현탁된 활성 화합물 (I)을 습윤 과립화에 도입하는 것을 특징으로 하는 방법.
- 제1항 또는 제2항에 있어서, 제약 조성물이 활성 화합물 (I)을 신속하게 방출하는 정제임을 특징으로 하는 방법.
- 제1항의 방법으로 제조된 경구 투여가능한 혈전색전성 질환의 예방 또는 치료용 고체 제약 조성물.
- 5-클로로-N-({(5S)-2-옥소-3-[4-(3-옥소-4-모르폴리닐)-페닐]-1,3-옥사졸리딘-5-일}-메틸)-2-티오펜카르복스아미드 [활성 화합물 (I)]를 친수화 형태로 포함하는 경구 투여가능한 혈전색전성 질환의 예방 또는 치료용 고체 제약 조성물.
- 제8항에 있어서, 활성 화합물 (I)을 결정질 형태로 포함하는 제약 조성물.
- 제9항에 있어서, 활성 화합물 (I)을 미분 형태로 포함하는 제약 조성물.
- 제7항 내지 제10항 중 어느 한 항에 있어서, 활성 화합물 (I)이 제제의 총 질량을 기준으로 1% 내지 60%의 농도로 존재하는 것을 특징으로 하는 제약 조성물.
- 제7항 내지 제10항 중 어느 한 항에 있어서, 습윤제로서 나트륨 라우릴 술페이트를 포함하는 제약 조성물.
- 제12항에 있어서, 나트륨 라우릴 술페이트를 총 질량을 기준으로 0.1% 내지 5%의 농도로 포함하는 제약 조성물.
- 제7항 내지 제10항 중 어느 한 항에 있어서, 친수성 결합제로서 히드록시프로필메틸셀룰로스를 포함하는 제약 조성물.
- 제14항에 있어서, 히드록시프로필메틸셀룰로스를 총 질량을 기준으로 1% 내지 15%의 농도로 포함하는 제약 조성물.
- 제7항 내지 제10항 중 어느 한 항에 있어서, 정제 형태인 제약 조성물.
- 제16항에 있어서, 신속 방출형 정제 형태인 제약 조성물.
- 제16항에 있어서, 정제가 코팅물로 도포된 것을 특징으로 하는 제약 조성물.
- 삭제
- 삭제
- 삭제
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10355461.0 | 2003-11-27 | ||
DE10355461A DE10355461A1 (de) | 2003-11-27 | 2003-11-27 | Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung |
PCT/EP2004/012897 WO2005060940A2 (de) | 2003-11-27 | 2004-11-13 | Verfahren zur herstellung einer festen, oral applizierbaren pharmazeutischen zusammensetzung |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20060117330A KR20060117330A (ko) | 2006-11-16 |
KR101151117B1 true KR101151117B1 (ko) | 2012-06-01 |
Family
ID=34609342
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020067010283A KR101151117B1 (ko) | 2003-11-27 | 2004-11-13 | 경구 투여가능한 고체 제약 조성물의 제조 방법 |
Country Status (35)
Country | Link |
---|---|
US (4) | US20080026057A1 (ko) |
EP (1) | EP1689370B2 (ko) |
JP (1) | JP4852423B2 (ko) |
KR (1) | KR101151117B1 (ko) |
CN (1) | CN1886120B (ko) |
AR (2) | AR047844A1 (ko) |
AT (1) | ATE385782T1 (ko) |
AU (1) | AU2004305226B2 (ko) |
BR (1) | BRPI0416404B8 (ko) |
CA (1) | CA2547113C (ko) |
CO (1) | CO5690540A2 (ko) |
CU (1) | CU23551B7 (ko) |
CY (1) | CY1107369T1 (ko) |
DE (2) | DE10355461A1 (ko) |
DK (1) | DK1689370T4 (ko) |
EC (1) | ECSP066584A (ko) |
ES (1) | ES2300845T5 (ko) |
GT (1) | GT200400239A (ko) |
HK (1) | HK1099518A1 (ko) |
HN (1) | HN2004000490A (ko) |
HR (1) | HRP20080150T4 (ko) |
IL (1) | IL175860B2 (ko) |
MA (1) | MA28178A1 (ko) |
MY (1) | MY138386A (ko) |
NO (1) | NO340156B1 (ko) |
NZ (1) | NZ547466A (ko) |
PE (1) | PE20050666A1 (ko) |
PL (1) | PL1689370T5 (ko) |
PT (1) | PT1689370E (ko) |
RU (2) | RU2379036C2 (ko) |
SI (2) | SI1689370T2 (ko) |
TW (1) | TWI356702B (ko) |
UA (1) | UA85693C2 (ko) |
WO (1) | WO2005060940A2 (ko) |
ZA (1) | ZA200604166B (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210085317A (ko) | 2019-12-30 | 2021-07-08 | 단국대학교 천안캠퍼스 산학협력단 | 자가나노유화 약물전달시스템을 이용한 리바록사반의 경구용 고형제 조성물 및 이의 제조방법 |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19962924A1 (de) | 1999-12-24 | 2001-07-05 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
DE10129725A1 (de) * | 2001-06-20 | 2003-01-02 | Bayer Ag | Kombinationstherapie substituierter Oxazolidinone |
DE10300111A1 (de) * | 2003-01-07 | 2004-07-15 | Bayer Healthcare Ag | Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid |
DE10355461A1 (de) | 2003-11-27 | 2005-06-23 | Bayer Healthcare Ag | Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung |
DE102004062475A1 (de) * | 2004-12-24 | 2006-07-06 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung |
EP1685841A1 (en) | 2005-01-31 | 2006-08-02 | Bayer Health Care Aktiengesellschaft | Prevention and treatment of thromboembolic disorders |
DE102005045518A1 (de) | 2005-09-23 | 2007-03-29 | Bayer Healthcare Ag | 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung |
EP1934208B1 (de) | 2005-10-04 | 2011-03-23 | Bayer Schering Pharma Aktiengesellschaft | Neue polymorphe form von 5-chlor-n-({ ( 5s )-2-0x0-3-[4-( 3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl} -methyl)-2-thiophencarboxamid |
DE102005047558A1 (de) * | 2005-10-04 | 2008-02-07 | Bayer Healthcare Ag | Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen |
DE102005047561A1 (de) * | 2005-10-04 | 2007-04-05 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung |
DE102006007146A1 (de) | 2006-02-16 | 2007-08-23 | Bayer Healthcare Ag | Aminoacyl-Prodrugs |
US8183287B2 (en) * | 2006-06-12 | 2012-05-22 | Schering Corporation | Pharmaceutical formulations and compositions of a selective antagonist of either CXCR2 or both CXCR1 and CXCR2 and methods of using the same for treating inflammatory disorders |
DE102006039589A1 (de) * | 2006-08-24 | 2008-03-06 | Bayer Healthcare Ag | Aminoacyl-Prodrugs II |
DE102006051625A1 (de) * | 2006-11-02 | 2008-05-08 | Bayer Materialscience Ag | Kombinationstherapie substituierter Oxazolidinone |
US20110045028A1 (en) * | 2006-11-30 | 2011-02-24 | Takeda Pharmaceutical Company Limited | Sustained release preparation |
MX2009006873A (es) * | 2006-12-22 | 2009-07-03 | Schering Corp | Promotores de desintegracion en formulaciones de granulacion humeda de dosis solida. |
JP5275815B2 (ja) * | 2006-12-26 | 2013-08-28 | 塩野義製薬株式会社 | リスペリドンを含有する口腔内崩壊錠剤および苦味抑制製剤 |
KR101424843B1 (ko) | 2007-03-29 | 2014-08-13 | 다이이찌 산쿄 가부시키가이샤 | 의약 조성물 |
DE102007028319A1 (de) * | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
DE102007028407A1 (de) * | 2007-06-20 | 2008-12-24 | Bayer Healthcare Ag | Substituierte Oxazolidinone und ihre Verwendung |
RU2457000C1 (ru) * | 2008-06-05 | 2012-07-27 | Брейн Бейс Корпорейшн | Костно-протезный материал и способ его изготовления |
US20110300214A1 (en) * | 2008-07-08 | 2011-12-08 | Ratiopharm Gmbh | Pharmaceutical compositions comprising 5-chloro-n-(-methyl)-2-thiophencarboxamid |
CA2733611A1 (en) * | 2008-08-11 | 2010-02-18 | Ratiopharm Gmbh | Pharmaceutical compositions with modified release properties comprising 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid |
US7816355B1 (en) | 2009-04-28 | 2010-10-19 | Apotex Pharmachem Inc | Processes for the preparation of rivaroxaban and intermediates thereof |
US20100287817A1 (en) * | 2009-05-14 | 2010-11-18 | Fmc Corporation | Method for Ant Control |
DK2442799T3 (da) | 2009-06-18 | 2017-01-02 | Krka Tovarna Zdravil D D Novo Mesto | Fast farmaceutisk sammensætning omfattende rivaroxaban |
EP2266541A1 (en) | 2009-06-18 | 2010-12-29 | Krka Tovarna Zdravil, D.D., Novo Mesto | Solid pharmaceutical composition comprising rivaroxaban |
EP2485715A1 (en) * | 2009-10-06 | 2012-08-15 | Ratiopharm GmbH | Pharmaceutical compositions comprising rivaroxaban |
EP2308472A1 (en) | 2009-10-06 | 2011-04-13 | ratiopharm GmbH | Pharmaceutical compositions comprising rivaroxaban |
HUE027168T2 (en) * | 2010-02-25 | 2016-10-28 | Bristol Myers Squibb Co | Apixaban formulations |
DE102010028362A1 (de) | 2010-04-29 | 2011-11-03 | Bayer Schering Pharma Aktiengesellschaft | Herstellverfahren |
EP2404920A1 (en) | 2010-07-06 | 2012-01-11 | Sandoz AG | Crystalline form of Rivaroxaban dihydrate |
US10004682B2 (en) * | 2010-08-24 | 2018-06-26 | Rutgers, The State University Of New Jersey | Formulation and manufacture of pharmaceuticals by impregnation onto porous carriers |
DE102010063127A1 (de) | 2010-12-15 | 2012-06-21 | Bayer Schering Pharma Aktiengesellschaft | Flüssige, oral applizierbare pharmazeutische Zusammensetzungen enthaltend 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid |
WO2013022924A1 (en) | 2011-08-08 | 2013-02-14 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical formulations |
UY34856A (es) * | 2012-07-03 | 2013-12-31 | Bayer Pharma AG | Formas de presentación farmacéuticas que contienen 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4- morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofencarboxamida |
EP2808011A1 (en) | 2013-05-29 | 2014-12-03 | Sandoz Ag | Process for the preparation of a pharmaceutical composition comprising Rivaroxaban |
CN104337787B (zh) * | 2013-08-06 | 2018-09-07 | 江苏豪森药业集团有限公司 | 含有利伐沙班的药物制剂 |
CN103550165B (zh) * | 2013-10-19 | 2019-07-16 | 浙江华海药业股份有限公司 | 一种含有利伐沙班的药物组合物及其制备方法 |
CN104721156B (zh) * | 2013-12-18 | 2020-05-01 | 山东新时代药业有限公司 | 一种含利伐沙班的片剂 |
WO2015124995A1 (en) | 2014-02-19 | 2015-08-27 | Aurobindo Pharma Ltd | Solid dosage forms of rivaroxaban |
CN104887633B (zh) * | 2014-03-04 | 2019-01-29 | 山东新时代药业有限公司 | 一种利伐沙班片剂及其制备方法 |
CN105078997A (zh) * | 2014-05-19 | 2015-11-25 | 广东东阳光药业有限公司 | 一种利伐沙班药用组合物及其制备方法 |
CN104173313B (zh) * | 2014-08-25 | 2017-05-17 | 杭州朱养心药业有限公司 | 利伐沙班片剂药物组合物 |
KR102271862B1 (ko) | 2014-12-31 | 2021-07-01 | 한미약품 주식회사 | 리바록사반 함유 경구용 고형제제 |
WO2016145375A1 (en) * | 2015-03-11 | 2016-09-15 | Plasmology4, Inc. | Container treatment system |
CN105078915A (zh) * | 2015-08-27 | 2015-11-25 | 江苏中邦制药有限公司 | 一种利伐沙班片及其制备方法 |
CN105287414A (zh) * | 2015-10-21 | 2016-02-03 | 南京百迪尔生物医药有限公司 | 一种含有利伐沙班的固体药物组合物及其制备方法 |
CN105267169B (zh) * | 2015-12-07 | 2018-03-30 | 石家庄康贺威药业有限公司 | 一种利伐沙班片剂及其制备方法 |
US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
CA3028346A1 (en) * | 2016-07-05 | 2018-01-11 | Alphamed Formulations Pvt. Ltd | Solid composition containing oral anticoagulant |
CN106109434B (zh) * | 2016-08-26 | 2019-04-05 | 乐普药业股份有限公司 | 一种利伐沙班片剂及其制备方法 |
JP6574041B2 (ja) * | 2017-12-15 | 2019-09-11 | エルメッド株式会社 | リバーロキサバン含有医薬組成物 |
EP3505160A1 (en) | 2017-12-31 | 2019-07-03 | Abdi Ibrahim Ilac Sanayi ve Ticaret A.S. | Preparation of a solid pharmaceutical composition comprising rivaroxaban and production thereof |
US10828310B2 (en) | 2018-02-02 | 2020-11-10 | Bayer Pharma Aktiengesellschaft | Reducing the risk of cardiovascular events |
CA3094431C (en) | 2018-03-19 | 2023-06-27 | Taiho Pharmaceutical Co., Ltd. | Pharmaceutical composition including sodium alkyl sulfate |
CN108864069B (zh) * | 2018-05-03 | 2021-04-20 | 华东理工大学 | 一种利伐沙班微粒及其制备方法与应用 |
GR1009619B (el) * | 2018-05-09 | 2019-10-23 | Φαρμαζακ Α.Φ.Ε.Β.Ε. | Φαρμακευτικη συνθεση που περιεχει ριβαροξαβανη και μεθοδος για την παρασκευη αυτης |
JP7305527B2 (ja) * | 2018-11-30 | 2023-07-10 | 大原薬品工業株式会社 | リバーロキサバンと嬌味剤を含有する固形製剤 |
CN112675136B (zh) * | 2019-10-18 | 2023-05-16 | 苏州特瑞药业股份有限公司 | 降低利伐沙班出血风险的组合物及其制备方法 |
US20210267908A1 (en) * | 2020-03-02 | 2021-09-02 | Mankind Pharma Ltd. | Pharmaceutical compositions of rivaroxaban |
EP4208462A1 (en) * | 2020-09-05 | 2023-07-12 | Inventia Healthcare Limited | Rivaroxaban compositions |
GR1010231B (el) | 2021-03-24 | 2022-05-10 | Φαρματεν Α.Β.Ε.Ε., | Φαρμακευτικο σκευασμα που περιλαμβανει ριβαροξαμπανη και μεθοδος παρασκευης αυτου |
CN113425729B (zh) * | 2021-06-24 | 2022-11-15 | 上海奥全生物医药科技有限公司 | 一种含有利伐沙班的药物组合物及其应用 |
WO2023067620A1 (en) * | 2021-10-18 | 2023-04-27 | Unison Pharmaceuticals Pvt. Ltd. | Orally disintegrating pharmaceutical compositions of rivaroxaban |
WO2023194885A1 (en) | 2022-04-08 | 2023-10-12 | Intas Pharmaceuticals Ltd. | An orodispersible tablet of rivaroxaban |
CN116869952A (zh) * | 2022-06-16 | 2023-10-13 | 北京四环制药有限公司 | 一种高稳定性的利伐沙班药物组合物及其制备方法 |
CN115590856A (zh) * | 2022-10-31 | 2023-01-13 | 南京海纳医药科技股份有限公司(Cn) | 一种含有利伐沙班的药物组合物及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998035663A1 (fr) * | 1997-02-17 | 1998-08-20 | Sanofi-Synthelabo | Formulations pharmaceutiques presentees sous forme seche pour l'administration orale d'un compose ammonium quaternaire cyclique |
WO2001047919A1 (de) * | 1999-12-24 | 2001-07-05 | Bayer Aktiengesellschaft | Substituierte oxazolidinone und ihre verwendung im gebiet der blutgerinnung |
Family Cites Families (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2811555A (en) | 1955-05-02 | 1957-10-29 | Eastman Kodak Co | Reduction of 2-nitroso-5-diethylaminotoluene |
US3279880A (en) | 1965-07-12 | 1966-10-18 | Eastman Kodak Co | Polyester textile material dyed with 1-hydroxy-4-n-p-(2'-pyrrolidonyl-1-) phenyl-amino anthraquinones |
LU80081A1 (fr) | 1977-08-26 | 1979-05-15 | Delalande Sa | Nouvelles hydroxymethyl-5 oxazolidinones-2,leur procede de preparation et leur application therapeutique |
US4128654A (en) | 1978-02-10 | 1978-12-05 | E. I. Du Pont De Nemours And Company | 5-Halomethyl-3-phenyl-2-oxazolidinones |
US4500519A (en) | 1978-11-06 | 1985-02-19 | Choay S.A. | Mucopolysaccharides having biological properties, preparation and method of use |
US4344934A (en) * | 1978-11-20 | 1982-08-17 | American Home Products Corporation | Therapeutic compositions with enhanced bioavailability |
JPS5611061A (en) | 1979-07-07 | 1981-02-04 | Seikichi Nakajima | Water circulation electrolytic device |
US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
HU190072B (en) | 1983-03-11 | 1986-08-28 | Biogal Gyogyszergyar,Hu | Process for production of medical preparatives with sinergetic influence |
NZ206600A (en) | 1983-05-11 | 1987-01-23 | Alza Corp | Osmotic drug delivery device |
US4765989A (en) | 1983-05-11 | 1988-08-23 | Alza Corporation | Osmotic device for administering certain drugs |
ES8506659A1 (es) | 1983-06-07 | 1985-08-01 | Du Pont | Un procedimiento para la preparacion de nuevos derivados del amino-metil-oxooxazolidinil-benzeno. |
DE3433239A1 (de) * | 1984-09-11 | 1986-03-20 | Bayer Ag, 5090 Leverkusen | Feste arzneizubereitung enthaltend nitrendipin und verfahren zu ihrer herstellung |
US4977173A (en) | 1987-10-21 | 1990-12-11 | E. I. Du Pont De Nemours And Company | Aminomethyl oxooxazolidinyl ethenylbenzene derivatives useful as antibacterial agents |
DE3884563T2 (de) | 1987-10-21 | 1994-02-17 | Du Pont Merck Pharma | Aminomethyl-oxo-oxazolidinyl-ethenylbenzen-Derivate, nützlich als antibakterielles Mittel. |
DE3822650A1 (de) | 1988-07-05 | 1990-02-01 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
US5254577A (en) | 1988-07-29 | 1993-10-19 | The Du Pont Merck Pharmaceutical Company | Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents |
US4948801A (en) | 1988-07-29 | 1990-08-14 | E. I. Du Pont De Nemours And Company | Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents |
TW212139B (ko) | 1991-04-15 | 1993-09-01 | Yamanouchi Pharma Co Ltd | |
AU667198B2 (en) | 1991-11-01 | 1996-03-14 | Pharmacia & Upjohn Company | Substituted aryl- and heteroarylphenyloxazolidinones useful as antibacterial agents |
SK283420B6 (sk) | 1992-05-08 | 2003-07-01 | Pharmacia & Upjohn Company | Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny |
US5349045A (en) | 1993-01-26 | 1994-09-20 | United States Surgical Corporation | Polymer derived from cyclic amide and medical devices manufactured therefrom |
DK0623615T3 (da) | 1993-05-01 | 1999-12-13 | Merck Patent Gmbh | Adhæsionsreceptor-antagonister |
US5688792A (en) | 1994-08-16 | 1997-11-18 | Pharmacia & Upjohn Company | Substituted oxazine and thiazine oxazolidinone antimicrobials |
DE4332384A1 (de) | 1993-09-23 | 1995-03-30 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten III |
RU2154645C2 (ru) | 1995-02-03 | 2000-08-20 | Фармация Энд Апджон Компани | Фенилоксазолидиноны, замещенные в кольце гетероароматическими кольцами, в качестве антимикробных агентов |
HRP960159A2 (en) | 1995-04-21 | 1997-08-31 | Bayer Ag | Benzocyclopentane oxazolidinones containing heteroatoms |
RU2158607C2 (ru) | 1995-07-03 | 2000-11-10 | Санкио Компани Лимитед | Лечение артериосклероза и ксантомы |
DE19524765A1 (de) | 1995-07-07 | 1997-01-09 | Boehringer Mannheim Gmbh | Neue Oxazolidinonderivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
US5968962A (en) | 1995-09-01 | 1999-10-19 | Pharmacia & Upjohn Company | Phenyloxazolidinones having a C-C bond to 4-8 membered heterocyclic rings |
DE69631347T2 (de) | 1995-09-15 | 2004-10-07 | Upjohn Co | Aminoaryl oxazolidinone n-oxide |
DE19601264A1 (de) | 1996-01-16 | 1997-07-17 | Bayer Ag | Pyrido-annellierte Thienyl- und Furanyl-Oxazolidinone |
HRP970049A2 (en) | 1996-02-06 | 1998-04-30 | Bayer Ag | New heteroaryl oxazolidinones |
DE19604223A1 (de) | 1996-02-06 | 1997-08-07 | Bayer Ag | Neue substituierte Oxazolidinone |
JP4328387B2 (ja) * | 1996-05-01 | 2009-09-09 | オーソ―マクニール・フアーマシユーチカル・インコーポレーテツド | 血栓形成疾患の処置のためのピロリジン、ピペリジン及びヘキサヒドロアゼピンのカルボキサミド誘導体 |
CN1228693A (zh) | 1996-06-28 | 1999-09-15 | 先灵公司 | 含有三唑类抗真菌化合物的口服组合物 |
GB9614238D0 (en) | 1996-07-06 | 1996-09-04 | Zeneca Ltd | Chemical compounds |
DE69734405T2 (de) | 1996-07-15 | 2006-08-03 | Sankyo Co., Ltd. | Verwendung von CS-866 (Olmersartan) zur Herstellung eines Medikaments für die Behandlung von Arteriosklerose |
FR2758459B1 (fr) * | 1997-01-17 | 1999-05-07 | Pharma Pass | Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation |
US5935724A (en) | 1997-04-04 | 1999-08-10 | Wilson Greatbatch Ltd. | Electrochemical cell having multiplate electrodes with differing discharge rate regions |
US6273913B1 (en) | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
WO1998054161A1 (en) | 1997-05-30 | 1998-12-03 | Pharmacia & Upjohn Company | Oxazolidinone antibacterial agents having a thiocarbonyl functionality |
KR20010021645A (ko) | 1997-07-11 | 2001-03-15 | 로렌스 티. 마이젠헬더 | 티아디아졸릴 및 옥사디아졸릴 페닐 옥사졸리디논 항균제 |
DE19730847A1 (de) | 1997-07-18 | 1999-01-28 | Bayer Ag | Tricyclisch substituierte Oxazolidinone |
DE19747261A1 (de) | 1997-10-25 | 1999-04-29 | Bayer Ag | Osmotisches Arzneimittelfreisetzungssystem |
SK284577B6 (sk) | 1997-11-12 | 2005-07-01 | Pharmacia & Upjohn Company | Deriváty oxazolidinónu, ich použitie a farmaceutické kompozície |
US6083967A (en) | 1997-12-05 | 2000-07-04 | Pharmacia & Upjohn Company | S-oxide and S,S-dioxide tetrahydrothiopyran phenyloxazolidinones |
DE19755268A1 (de) | 1997-12-12 | 1999-06-17 | Merck Patent Gmbh | Benzamidinderivate |
DE19802239A1 (de) | 1998-01-22 | 1999-07-29 | Bayer Ag | Neue mit Bicyclen substituierte Oxazolidinone |
CA2318969A1 (en) | 1998-01-23 | 1999-07-29 | Mikhail F. Gordeev | Oxazolidinone combinatorial libraries, compositions and methods of preparation |
ZA99607B (en) | 1998-01-27 | 1999-07-27 | Rhone Poulenc Rorer Pharma | Substituted oxoazaheterocyclyl factor xa inhibitors. |
DE19805117A1 (de) | 1998-02-09 | 1999-08-12 | Bayer Ag | Neue Oxazolidinone mit azolhaltigen Tricyclen |
US20010029351A1 (en) | 1998-04-16 | 2001-10-11 | Robert Falotico | Drug combinations and delivery devices for the prevention and treatment of vascular disease |
CA2327100A1 (en) | 1998-05-18 | 1999-11-25 | Pharmacia & Upjohn Company | Enhancement of oxazolidinone antibacterial agents activity by using arginine derivatives |
DE19842753A1 (de) | 1998-09-18 | 2000-03-23 | Bayer Ag | Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung |
SA99191255B1 (ar) | 1998-11-30 | 2006-11-25 | جي دي سيرل اند كو | مركبات سيليكوكسيب celecoxib |
US6413981B1 (en) | 1999-08-12 | 2002-07-02 | Ortho-Mcneil Pharamceutical, Inc. | Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods |
PE20010851A1 (es) | 1999-12-14 | 2001-08-17 | Upjohn Co | Esteres del acido benzoico de oxazolidinonas que tienen un substituyente hidroxiacetilpiperazina |
CA2389482A1 (en) | 1999-12-21 | 2001-06-28 | Jackson B. Hester, Jr. | Oxazolidinones having a sulfoximine functionality and their use as antimicrobial agents |
AU2225901A (en) | 1999-12-28 | 2001-07-09 | Ajinomoto Co., Inc. | Aspartame derivative crystals |
US6514529B2 (en) * | 2000-03-22 | 2003-02-04 | Pharmacia & Upjohn Company | Oxazolidinone tablet formulation |
PE20020300A1 (es) | 2000-08-22 | 2002-05-10 | Pharmacia Corp | Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco |
KR100415318B1 (ko) | 2000-09-23 | 2004-01-16 | 탁승호 | 레이저를 이용한 수평 및 수직선 지시계 |
WO2002038126A2 (en) | 2000-11-08 | 2002-05-16 | Aeromatic-Fielder Ag | A process for production of particles for pharmaceutical compositions having increased bioavailability |
KR20030076634A (ko) | 2001-01-30 | 2003-09-26 | 데이진 가부시키가이샤 | 의약 조성물 |
DE10105989A1 (de) | 2001-02-09 | 2002-08-14 | Bayer Ag | Substituierte Oxazolidinone und ihre Verwendung |
DE10110438A1 (de) | 2001-03-05 | 2002-09-19 | Bayer Ag | Substituierte 2-Oxy-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
DE10110747A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte 2,6-Diamino-3,5-dicyano-4-aryl-pyridine und ihre Verwendung |
DE10110754A1 (de) | 2001-03-07 | 2002-09-19 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
DE10115922A1 (de) | 2001-03-30 | 2002-10-10 | Bayer Ag | Cyclisch substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
DE10115945A1 (de) | 2001-03-30 | 2002-10-02 | Bayer Ag | Substituierte 2-Carba-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
DE10129725A1 (de) | 2001-06-20 | 2003-01-02 | Bayer Ag | Kombinationstherapie substituierter Oxazolidinone |
DE10134481A1 (de) | 2001-07-16 | 2003-01-30 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung |
DE10152460A1 (de) | 2001-10-24 | 2003-05-08 | Bayer Ag | Stents |
DE10238113A1 (de) | 2001-12-11 | 2003-06-18 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung |
US20030161882A1 (en) | 2002-02-01 | 2003-08-28 | Waterman Kenneth C. | Osmotic delivery system |
DE10300111A1 (de) | 2003-01-07 | 2004-07-15 | Bayer Healthcare Ag | Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid |
DE10355461A1 (de) | 2003-11-27 | 2005-06-23 | Bayer Healthcare Ag | Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung |
DE102004002044A1 (de) | 2004-01-15 | 2005-08-04 | Bayer Healthcare Ag | Herstellverfahren |
DE102004062475A1 (de) | 2004-12-24 | 2006-07-06 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung |
EP1685841A1 (en) | 2005-01-31 | 2006-08-02 | Bayer Health Care Aktiengesellschaft | Prevention and treatment of thromboembolic disorders |
DE102005045518A1 (de) | 2005-09-23 | 2007-03-29 | Bayer Healthcare Ag | 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung |
DE102005047561A1 (de) | 2005-10-04 | 2007-04-05 | Bayer Healthcare Ag | Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung |
EP1934208B1 (de) | 2005-10-04 | 2011-03-23 | Bayer Schering Pharma Aktiengesellschaft | Neue polymorphe form von 5-chlor-n-({ ( 5s )-2-0x0-3-[4-( 3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl} -methyl)-2-thiophencarboxamid |
DE102005047558A1 (de) | 2005-10-04 | 2008-02-07 | Bayer Healthcare Ag | Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen |
DE102005048824A1 (de) | 2005-10-10 | 2007-04-12 | Bayer Healthcare Ag | Behandlung und Prophylaxe von Mikroangiopathien |
DE102006034916A1 (de) | 2006-07-28 | 2008-01-31 | Bayer Healthcare Ag | Beschichtung künstlicher Oberflächen von medizinischen Hilfsmitteln und Geräten sowie Reinigung und/oder Vorbehandlung von Kathetern und anderen medizinischen Hilfsmitteln und Geräten |
DE102006051625A1 (de) | 2006-11-02 | 2008-05-08 | Bayer Materialscience Ag | Kombinationstherapie substituierter Oxazolidinone |
-
2003
- 2003-11-27 DE DE10355461A patent/DE10355461A1/de not_active Withdrawn
-
2004
- 2004-10-29 AR ARP040103985A patent/AR047844A1/es not_active Application Discontinuation
- 2004-11-13 CA CA2547113A patent/CA2547113C/en active Active
- 2004-11-13 AT AT04797879T patent/ATE385782T1/de active
- 2004-11-13 AU AU2004305226A patent/AU2004305226B2/en active Active
- 2004-11-13 DE DE502004006218T patent/DE502004006218D1/de active Active
- 2004-11-13 PL PL04797879T patent/PL1689370T5/pl unknown
- 2004-11-13 JP JP2006540276A patent/JP4852423B2/ja active Active
- 2004-11-13 UA UAA200607192A patent/UA85693C2/ru unknown
- 2004-11-13 EP EP04797879.6A patent/EP1689370B2/de active Active
- 2004-11-13 IL IL175860A patent/IL175860B2/en active IP Right Grant
- 2004-11-13 WO PCT/EP2004/012897 patent/WO2005060940A2/de active IP Right Grant
- 2004-11-13 SI SI200430675A patent/SI1689370T2/sl unknown
- 2004-11-13 US US10/580,711 patent/US20080026057A1/en not_active Abandoned
- 2004-11-13 PT PT04797879T patent/PT1689370E/pt unknown
- 2004-11-13 KR KR1020067010283A patent/KR101151117B1/ko active IP Right Review Request
- 2004-11-13 BR BRPI0416404A patent/BRPI0416404B8/pt active IP Right Grant
- 2004-11-13 DK DK04797879.6T patent/DK1689370T4/da active
- 2004-11-13 NZ NZ547466A patent/NZ547466A/en unknown
- 2004-11-13 CN CN200480035106XA patent/CN1886120B/zh active Active
- 2004-11-13 RU RU2006122599/15A patent/RU2379036C2/ru active
- 2004-11-13 ES ES04797879.6T patent/ES2300845T5/es active Active
- 2004-11-13 SI SI200430675T patent/SI1689370T1/sl unknown
- 2004-11-23 GT GT200400239A patent/GT200400239A/es unknown
- 2004-11-25 HN HN2004000490A patent/HN2004000490A/es unknown
- 2004-11-25 MY MYPI20044891A patent/MY138386A/en unknown
- 2004-11-26 TW TW093136394A patent/TWI356702B/zh active
- 2004-11-26 PE PE2004001166A patent/PE20050666A1/es active IP Right Grant
-
2006
- 2006-05-23 CO CO06049473A patent/CO5690540A2/es unknown
- 2006-05-24 MA MA29056A patent/MA28178A1/fr unknown
- 2006-05-24 ZA ZA200604166A patent/ZA200604166B/en unknown
- 2006-05-25 EC EC2006006584A patent/ECSP066584A/es unknown
- 2006-05-29 CU CU20060109A patent/CU23551B7/es active IP Right Grant
- 2006-06-23 NO NO20062942A patent/NO340156B1/no unknown
-
2007
- 2007-06-22 HK HK07106689.6A patent/HK1099518A1/xx unknown
-
2008
- 2008-03-27 CY CY20081100352T patent/CY1107369T1/el unknown
- 2008-04-01 HR HRP20080150TT patent/HRP20080150T4/hr unknown
-
2009
- 2009-07-16 RU RU2009127302/15A patent/RU2493850C2/ru active Protection Beyond IP Right Term
-
2014
- 2014-03-10 US US14/202,481 patent/US9402851B2/en active Active
- 2014-04-11 US US14/250,863 patent/US9415053B2/en active Active
-
2016
- 2016-02-10 US US15/040,169 patent/US20170007612A1/en not_active Abandoned
- 2016-05-31 AR ARP160101594A patent/AR104840A2/es not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998035663A1 (fr) * | 1997-02-17 | 1998-08-20 | Sanofi-Synthelabo | Formulations pharmaceutiques presentees sous forme seche pour l'administration orale d'un compose ammonium quaternaire cyclique |
WO2001047919A1 (de) * | 1999-12-24 | 2001-07-05 | Bayer Aktiengesellschaft | Substituierte oxazolidinone und ihre verwendung im gebiet der blutgerinnung |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210085317A (ko) | 2019-12-30 | 2021-07-08 | 단국대학교 천안캠퍼스 산학협력단 | 자가나노유화 약물전달시스템을 이용한 리바록사반의 경구용 고형제 조성물 및 이의 제조방법 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101151117B1 (ko) | 경구 투여가능한 고체 제약 조성물의 제조 방법 | |
US20200163882A1 (en) | Solid Pharmaceutical Compositions Of Androgen Receptor Antagonists | |
JP5714492B2 (ja) | 粒状体、それらの調製方法、およびそれらを含む医薬品 | |
TWI228414B (en) | Pharmaceutical composition comprising carvedilol and hydrochlorothiazide, solid dosage form comprising it, and process for the production of the same | |
WO2012043709A1 (ja) | 難溶性薬物の溶解性改善製剤 | |
JP2014040475A (ja) | 新規製剤 | |
JP2010519200A (ja) | シロスタゾールを含む制御放出製剤及びその製造方法 | |
JP6199922B2 (ja) | 化学的な安定性が向上したイルベサルタン含有錠剤 | |
GR1009619B (el) | Φαρμακευτικη συνθεση που περιεχει ριβαροξαβανη και μεθοδος για την παρασκευη αυτης | |
WO2022162687A1 (en) | Pharmaceutical compositions comprising nilotinib | |
MXPA06005846A (en) | Method for the production of a solid, orally applicable pharmaceutical composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
N231 | Notification of change of applicant | ||
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
J204 | Request for invalidation trial [patent] | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J204 | Request for invalidation trial [patent] | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
FPAY | Annual fee payment |
Payment date: 20150430 Year of fee payment: 4 |
|
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J301 | Trial decision |
Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20150313 Effective date: 20151103 Free format text: TRIAL DECISION FOR INVALIDATION REQUESTED 20150310 Effective date: 20151103 Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20150325 Effective date: 20151103 Free format text: TRIAL NUMBER: 2015100000770; TRIAL DECISION FOR INVALIDATION REQUESTED 20150310 Effective date: 20151103 Free format text: TRIAL NUMBER: 2015100000844; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20150313 Effective date: 20151103 Free format text: TRIAL NUMBER: 2015100001221; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20150325 Effective date: 20151103 |
|
J2X1 | Appeal (before the patent court) |
Free format text: INVALIDATION Free format text: TRIAL NUMBER: 2015200008455; INVALIDATION |
|
FPAY | Annual fee payment |
Payment date: 20160427 Year of fee payment: 5 |
|
J202 | Request for trial for correction [limitation] | ||
J302 | Written judgement (patent court) |
Free format text: TRIAL NUMBER: 2015200008691; JUDGMENT (PATENT COURT) FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20151230 Effective date: 20161013 Free format text: TRIAL NUMBER: 2015200008455; JUDGMENT (PATENT COURT) FOR INVALIDATION REQUESTED 20151223 Effective date: 20161013 Free format text: TRIAL NUMBER: 2015200008707; JUDGMENT (PATENT COURT) FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20151230 Effective date: 20161013 |
|
FPAY | Annual fee payment |
Payment date: 20170504 Year of fee payment: 6 |
|
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2016105000136; TRIAL DECISION FOR CORRECTION REQUESTED 20161118 Effective date: 20170905 |
|
FPAY | Annual fee payment |
Payment date: 20180427 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20190429 Year of fee payment: 8 |
|
J206 | Request for trial to confirm the scope of a patent right | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2019100003870; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20191204 Effective date: 20200623 Free format text: TRIAL NUMBER: 2020100000256; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20200122 Effective date: 20200623 Free format text: TRIAL NUMBER: 2020100001129; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20200407 Effective date: 20200623 |
|
J206 | Request for trial to confirm the scope of a patent right | ||
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2020100002184; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20200720 Effective date: 20200831 |
|
J303 | Written judgement (supreme court) |
Free format text: TRIAL NUMBER: 2016300002584; JUDGMENT (SUPREME COURT) FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20161117 Effective date: 20201224 |
|
J303 | Written judgement (supreme court) |
Free format text: TRIAL NUMBER: 2016300002577; JUDGMENT (SUPREME COURT) FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20161117 Effective date: 20201224 |
|
J303 | Written judgement (supreme court) |
Free format text: TRIAL NUMBER: 2016300002560; JUDGMENT (SUPREME COURT) FOR INVALIDATION REQUESTED 20161117 Effective date: 20201224 |
|
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2021130000006; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20210114 Effective date: 20210521 |
|
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2021130000009; TRIAL DECISION FOR INVALIDATION REQUESTED 20210115 Effective date: 20210716 |
|
J206 | Request for trial to confirm the scope of a patent right | ||
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2021100003708; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20211216 Effective date: 20220725 |